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Abstract
The purpose of this chapter is to review the concept of adherence and analyze its implica-
tions for the social construction of the patient as a subject, since this affects the relation-
ship established with the health services for the maintenance of care. The facilitators and 
barriers to adherence reported in the literature are presented, based on studies focused 
on the perspective of people living with HIV. At the end of the chapter, the individual 
elements that promote adherence to treatment are shown, according to the experience of 
highly adherent patients. In addition, individual and contextual barriers to the adherence 
process are identified in the pharmacological and nonpharmacological dimensions.
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1. Introduction
The development of highly active antiretroviral treatment (HAART) has allowed HIV infec-
tion to become a chronic condition. This historic event has transformed the experience of peo-
ple living with HIV, since it has allowed them to extend their survival time and increase their 
quality of life [1]. However, this biomedical breakthrough has generated important challenges 
for public health. One of them is universal access to treatment. Social inequality in terms of 
the intersection between gender, social class, ethnic group, sexual orientation, or geographi-
cal region places patients at different levels of vulnerability regarding access to treatment. 
Likewise, social inequality affects the continuity of long-term treatment, as patients differ 
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in access to services that allow maintaining care over time as food, education, health, hous-
ing, employment, and transportation, among others. For this reason, public health cannot be 
limited to a “pharmaceuticalization” or exclusive emphasis on access to medication, but it 
requires considering the social and economic conditions that affect the possibilities of patients 
to maintain a long-term pharmacological treatment [2].
The second challenge, which is addressed in this chapter, is the promotion of adherence to 
treatment in people living with HIV. This challenge is linked to the facilitation of psychosocial 
processes that allow long-term adherence, while the previous challenge focuses mainly on the 
structural conditions associated with adherence. Unlike pharmacological treatment for other 
medical conditions, HAART requires an efficacy greater than 95% to control the number of 
copies of the virus in the body. The suboptimal medication intake is associated with higher 
levels of morbidity and mortality as well as the emergence of drug-resistant viral strains. This 
reduces the effectiveness of subsequent treatment schemes [3].
The lack of adherence to treatment has multiple consequences for the state: increased expenses 
for hospitalization, care for opportunistic infections, and changes in treatment schemes and 
laboratory studies. In turn, lack of adherence increases the risk of HIV transmission in popu-
lations and the development of new strains resistant to treatment [4].
The study of adherence to treatment in people living with HIV has focused mainly on phar-
macological adherence. It is necessary to develop a comprehensive perspective on adherence, 
which not only includes medication intake but also the adoption of a healthy lifestyle in mul-
tiple areas. The following section analyzes the concept of adherence and its influence on the 
patient’s relationship with health services.
2. Perspectives on adherence
The social construction of adherence influences the way in which patients are constituted as 
subjects, the type of relationships they establish with health personnel, and the policies of 
health services for patient care. Previously the term “compliance” was used to refer to the 
degree to which the patient followed medical recommendations for taking the medication or 
making lifestyle changes. The concept was criticized because it assumed a hierarchical rela-
tionship between the doctor and the patient, considered that the medical recommendations 
were correct and that the failure in the treatment was mainly the responsibility of the patient 
for not complying with the recommendations [5].
In contrast, the concept of adherence emerged in a historical moment where patients had 
greater access to information technologies, which expanded the possibilities of having infor-
mation about their diagnosis and treatment. This allowed patients to develop a sense of 
agency, establish a dialog with health personnel and adopt a critical stance during the treat-
ment process. Likewise, the emergence of chronic conditions sets limits to the power of health 
personnel and forced the incorporation of the patient in the planning and maintenance of 
long-term care.
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Adherence means a different type of relationship to “compliance”: a horizontal, democratic, 
and collaborative relationship for the maintenance of care over time. The concept not only 
implies a change in the relationship with health personnel; it also represents a change in the 
subject: the patient becomes an active agent in the treatment process. Health services not only 
attribute responsibility to the patient for taking the medication or following the health recom-
mendations; they also encourage the patient to request information about their health status 
and to participate in decision-making during treatment. It should be noted that this notion of 
the patient is based on two assumptions: care depends on the patient’s will, and the patient is 
interested in maintaining or improving their health status.
From biomedical discourse, it is assumed that subjects are able to choose; act rationally, inten-
tionally, and responsibly; and make decisions in terms of costs and benefits. However, the pos-
sibility of deciding is determined structurally. This means that the subjects are not completely 
free to decide; they can select the possibilities available for their local context, according to 
their socioeconomic position and the dominant cultural values [6]. As previously mentioned, 
social inequality not only affects access to treatment; it also limits access to services that favor 
the maintenance of care and the patient’s ability to become adherent.
In the particular case of HIV infection, there are two additional elements that affect the devel-
opment of adherence. The social processes of stigma and discrimination [7] contribute to the 
exclusion of patients from health services, the delay in diagnosis, the rejection of the medical 
condition and treatment, the concealment of the diagnosis, and the reduction of social sup-
port. Close connection with these processes is the emotional discomfort, because the suffering 
caused by knowing the serological status can manifest itself in rejection toward diagnosis and 
health services; the development of risk practices or the appearance of a psychological disor-
der that limits the capacity for health care [8].
While it is important to consider that adherence requires an active agent in their self-care 
that maintains a collaborative relationship with health services, it is also assumed that the 
patient’s agency is limited. There are different possibilities for patients to become adherents, 
due to structural inequalities, the processes of stigma and discrimination, and the emotional 
distress generated by the HIV diagnosis. Therefore, adherence is not a state that is achieved 
by all patients at the same time.
It is more appropriate to consider adherence as a dynamic process that develops over time [9], 
influenced by the social, economic, and cultural context surrounding the patient. Adherence 
is also affected by the learning process that arises from the patient’s personal experience with 
diagnosis and treatment. This means that people living with HIV have different temporalities 
and rhythms to become adherent patients. Adherence is not a state that is reached once and 
for all, but a process that must be continually updated. At any point in treatment, the patient 
can become nonadherent, either intentionally or involuntarily [10].
From an integral perspective of patient care, it is assumed that there are two complementary 
dimensions of adherence. The first dimension is pharmacological adherence, which involves 
taking the medication and following the instructions in terms of the schedule and the food 
that accompanies the intake [3]. Previous studies have reported adherence rates ranging from 
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26–89% [11–14]. The variability in reported adherence rates depends on the operational defi-
nition of adherence and the instrument used for its measurement [15]. The pharmacological 
adherence is overestimated when it is calculated based on the ratio of pills forgotten and 
prescribed in the last days. A more precise evaluation requires the inclusion of aspects such as 
the follow-up of the schedule and special instructions or the last missed dose [16]. It is worth 
mentioning that several patterns of pharmacological nonadherence have been identified: dif-
ficulties to initiate treatment, temporary suspension (whose duration is variable), or definitive 
abandonment, which represents a long-term pattern [17]. Nonadherence may be due to error 
or forgetfulness of the medication intake, as well as the conscious decision to abandon the 
treatment or not follow it properly [10].
The patient not only decides whether or not to initiate HAART but also decides whether to 
adopt a new lifestyle. The second dimension is associated with nonpharmacological adher-
ence, which encompasses a set of practices that promote the patient’s health care. It includes 
practices in the areas of diet, physical activity, rest, sexual health, mental health, attendance at 
medical appointments and attendance to laboratory studies, and avoidance of alcohol, tobacco, 
or other substances. Medication intake needs to be complemented by a series of healthy prac-
tices to promote the care of the patient and the improvement of their quality of life.
Adherence can be conceived as a process that develops over time. This process is affected by 
the socioeconomic position of the patient in a certain context, the dominant cultural values, 
and his personal experience with illness. At any point of time, the patient may be adherent or 
nonadherent. To be adherent, the patient needs to follow both pharmacological and nonphar-
macological treatment. However, there is a risk that the patient develops patterns of nonad-
herence (pharmacological or nonpharmacological), which occur in the short term (at a point 
in time) or in the medium and long terms (at multiple time points) (Figure 1).
Four possible scenarios can be contemplated in a single moment of the treatment: (1) The 
patient is adherent at the pharmacological and nonpharmacological level (ideal scenario); 
Figure 1. Adherence and nonadherence to treatment at a time point.
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(2) the patient is adherent at the pharmacological level, but not at the nonpharmacological 
level (scenario where the patient takes the medication, but does not perform the other types 
of care); (3) the patient is adherent at the nonpharmacological level, but not at the pharmaco-
logical level (scenario where the patient performs healthcare practices, but does not take the 
medication according to the indications); and (4) the patient is not adherent in both dimen-
sions (the worst-case scenario).
It should be mentioned that the identification of a patient as adherent will depend on the way 
in which the health personnel evaluate the taking of the medication and the recommendations 
of food and schedule (pharmacological adherence), as well as the evaluation of the degree of 
accomplishment of the practices in different areas of care (nonpharmacological adherence). 
Adherence can be considered in terms of degrees of a continuum; however, it is also necessary 
to establish what is the sufficient level of pharmacological and nonpharmacological adher-
ence. This implies the need for a continuous dialog between the patient and the health person-
nel, in order to determine the levels of pharmacological and nonpharmacological adherence 
required, collaborate in the monitoring of the types of adherence, and receive feedback on the 
actions performed by both actors to maintain adherence.
Before reaching an optimal level of adherence, patients can alternate between periods of 
adherence and nonadherence until achieving an adequate and stable adherence. Traditionally 
it has been considered that patients are rational subjects who make a balance between the 
benefits and the costs of treatment to decide if they will remain adherent. However, it is nec-
essary to consider the affective dimension, since patients not only accept treatment, they can 
also experience ambivalence or rejection toward treatment. It is necessary to remember that 
illness generates discomfort in function of the rupture it causes in the life of patients, since it 
affects their biography, identity, daily world, and social relations. Patients not only have the 
task of taking care of their health and adhering to treatment, simultaneously they embark on 
the tasks of giving meaning to life with the HIV infection and the reconstruction of their social 
world to incorporate illness in everyday life [18].
Adherence can be seen as a dialectical process where facilitators and barriers coexist dur-
ing treatment. In the next section, the main facilitators and barriers to adherence reported 
in the literature, whether at the individual, interpersonal, or contextual levels will be 
reviewed.
3. Facilitators and barriers to adherence to treatment in people living 
with HIV
In the literature, several factors associated with adherence to treatment have been reported. 
A series of studies have identified the following factors based on cross-sectional studies, from 
the perspective of the researchers [19]:
• Factors related to personal attributes. They include the patient’s clinical status, educational 
level, income, access to housing, and stability of the home.
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• Factors related to the treatment regimen. It has been found that adherence is affected by the 
complexity of the regimen (depending on the number of pills or the type of indications for 
taking the medication), the ease of adapting the treatment to daily life, the use of devices 
for adherence (such as pillboxes or alarms), or side effects of treatment.
• Psychological factors. This level includes cognitive aspects such as concentration difficul-
ties or forgetting, understanding of the role of antiretroviral treatment, or knowledge about 
the medical condition. Attitudes toward illness, treatment, and medications are also con-
sidered. Negative mental health factors include depression, hopelessness, anxiety or other 
types of psychiatric morbidity, alcohol or drug use, and coping through avoidance strate-
gies. Positive factors include a positive attitude toward the future, long-term plans and 
goals, active coping, and stable mental health.
• Social factors. The relationship with the health service provider, the social support avail-
able, and the fear of revealing the diagnosis (linked to social processes of stigma and dis-
crimination) have been identified.
• Structural factors. It includes access to treatment and health services, also economic re-
sources to stay in treatment.
In another series of studies based on qualitative methods, facilitators and barriers to adher-
ence have been identified from the perspective of people living with HIV. A facilitator is any 
individual attribute (physical, cognitive, emotional, or behavioral), characteristic of treatment, 
interpersonal process, or contextual aspect that favors the adherence process. In opposition, 
a barrier is the individual attribute, characteristic of treatment, interpersonal process, or con-
textual aspect that limits the adherence process.
At the individual level, beliefs that facilitate adherence have been found, such as the recogni-
tion of the drug’s role in the prevention of death and illness, the perception of medicine as 
responsible for the improvement of health and well-being, the establishment of the main-
tenance of health as a priority, and religious beliefs. At an affective and motivational level, 
adherence is facilitated by the fear of experiencing opportunistic infections or hospitaliza-
tions, getting used to the presence of side effects, the emotional work of appropriating the 
suffering and feeling pride in their coping, having incentives as significant persons or future 
plans, adopting an optimistic perspective toward the future, or the will to live [20–25].
Other aspects that influence adherence are related to the impact of treatment, such as the 
absence of side effects or the clinical results of treatment. Among the practices that promote 
adherence are the use of external reminders, taking the medicine when the patient needs to 
leave the home, dealing with side effects, self-monitoring of symptoms and energy level, and 
conducting laboratory studies. Over time, taking the medication becomes a habit that is per-
formed automatically [20–25].
Among the contextual aspects that facilitate adherence are having a stable lifestyle, the 
inclusion of treatment in the lifestyle, and the association of medication intake with 
daily routines. At the interpersonal level, there are facilitators such as access to positive 
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sources of social support and the maintenance of a collaborative relationship with health 
personnel [20–26].
As has happened with the facilitators, the main barriers have been identified at the individ-
ual level. Adherence is affected by beliefs about antiretroviral treatment, lack of information 
about treatment, beliefs about illness, as well as minimizing the risks of living with HIV. It is 
also affected by aspects associated with the patient’s physical condition, such as forgetfulness, 
fatigue, or feeling sick. Even self-care can be neglected when the patient perceives a good 
health status. At the affective level, adherence is limited by the emotional impact of diagnosis, 
lack of acceptance, or rejection of treatment because it remembers the presence of HIV. Other 
aspects that hinder adherence are the fatigue of medication, anger, depression, despair, or 
other vital concerns beyond health [23–27].
The barriers to adherence associated with the patient’s context are the interference of treat-
ment with the daily routine, the changes in the routine, and the workload or being out of 
home during the moment of medicine intake. At the interpersonal level, adherence is limited 
by the lack of social support and conflicts in the relationship with health personnel [20, 22, 25]. 
There are also barriers linked to social inequality. Some are of an economic nature, such as 
the difficulty to cover the expenses required for transportation to medical appointments or 
to maintain an appropriate diet [23, 24]. Other barriers are related to the internalization of 
stigma and the fear of discrimination. There are also barriers associated with gender inequal-
ity, such as differences in access to medical services and treatment or in the negotiation of 
condom use, especially when the couple denies the diagnosis of HIV [28]. Men may reject 
adherence as a form of resistance to “body discipline” [26].
In the previous section, it was mentioned that at any time during the treatment process, the 
patient faces the dilemma of adhering or not adhering. Adherence involves both taking the 
medication according to the specified conditions and adopting a healthy lifestyle in multiple 
areas. It should be added that at each moment of the treatment process, the patient encounters 
multiple facilitators and barriers to adherence (Figure 2).
At the individual level, there are facilitators and barriers of different types: physical, cog-
nitive, affective, motivational, and practical. Traditionally, health psychology has focused 
on modifying these elements to promote adherence. However, there are also facilitators 
and barriers at the interpersonal level, specifically linked to social relationships established 
in areas such as family, friends, health services, or the community. At this level, different 
types of interventions are required: family interventions, interventions focused on provid-
ing social support or expanding the patient’s network, interventions focused on improving 
interaction with health personnel, and interventions to modify the organization of health 
services.
Finally, there are facilitators and barriers that are part of the patient’s life context: daily rou-
tines, work and home conditions, and economic conditions. There are also conditions that can 
limit access and permanence in health services, such as gender inequality and social processes 
of stigma and discrimination. This level needs to be considered not only to adjust the treatment 
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to the context of the patient’s life but also to develop social interventions and public policies 
that benefit the adherence of patients in conditions of greater social vulnerability.
The identification of facilitators allows health personnel to understand the elements that con-
tribute to the maintenance of good adherence by the patient, whether in the pharmacological 
or nonpharmacological dimension. The identification of barriers allows health personnel to 
provide feedback to the patient on those individual, interpersonal, or contextual aspects that 
limit the treatment and to plan the interventions required to improve the level of adherence 
(at the individual or collective level). It can even help in the anticipation of relapses, since both 
the patient and the health personnel can work collaboratively to design and implement strate-
gies that reduce the impact of the barriers.
The following section shows how the facilitators interact to promote adherence, from the 
perspective of highly adherent patients. Likewise, barriers reported by these patients are 
identified, both for pharmacological and nonpharmacological adherence. This last type of 
adherence is not usually represented in adherence studies of people living with HIV.
4. Maintain adherence to antiretroviral treatment: perspective of 
highly adherent patients
From an individual level, the adherence process requires the interaction of different dimen-
sions. The first dimension covers the beliefs that patients construct about illness and  treatment. 
Figure 2. Facilitators and barriers to adherence to treatment, at different levels.
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Patients with high levels of adherence believe that HIV infection acts by replicating the virus 
within the body and decreasing the defenses, allowing the appearance of symptoms and dis-
eases. In opposition to the beliefs about illness, they consider that HAART stops the virus 
and allows the defenses to increase, which strengthens the immune system. Although they 
recognize the benefits of pharmacological treatment, the main cost is the presence of side 
effects. The short-term effects are perceived as temporary and as indicators of an adaptation 
of the body. They mainly recognize gastrointestinal symptoms and alterations in mood or 
perception. Long-term effects are perceived as more damaging, due to their impact on physi-
cal appearance, metabolism, internal organs, or sensory and motor alterations [29].
Although the knowledge of common sense about illness can vary according to the cultural 
context of the patient, its socioeconomic position, or its level of education, it is important to 
point out that patients need to elaborate a basic explanatory model based on the relationship 
with health personnel and the education they get about their medical condition. This explana-
tory model establishes a common basis for collaboration with health services, since it allows 
to give meaning to care practices and to recognize their own vulnerability. Possibly beliefs 
about illness contribute to the identification of the threat and susceptibility to HIV infection, 
while beliefs about treatment favor the identification of the benefits in the care process. A 
crucial aspect is that the patient evaluates the benefits of the treatment more favorably than 
the costs of the side effects.
Patients also elaborate beliefs about adherence to treatment. This process is mainly associated 
with taking the medication, which may imply that greater importance is attached to the phar-
macological adherence. This not only reflects the interests of the patient, since in the health 
services, there is also a greater concern for monitoring medication intake. In addition to tak-
ing the medication, patients consider that maintaining adherence requires two fundamental 
conditions. One of them is responsibility, because becoming a patient involves adopting the 
discipline of treatment.
The second condition is that patients maintain the desire to live, instead of “falling emotion-
ally.” This refers to the situation in which patients deny or reject the diagnosis, or they are 
depressed and put their health at risk. Therefore, in order to maintain the medication intake 
over time, patients need to accept the diagnosis and keep the will to live. Only in this way can 
patients take responsibility for their own care and incorporate the treatment discipline into 
their daily life, for a long period of time [29].
To stay under treatment, it is essential that patients anticipate the consequences if they do 
not adhere. These are the main consequences associated with nonadherence: (1) the treat-
ment will stop working; (2) the virus is going to replicate; (3) the virus is going to become 
resistant; and (4) the problems will begin, such as the decrease of defenses and the emergence 
of diseases. It should be noted that the anticipated consequences are consistent with beliefs 
about illness and treatment. Another aspect that needs to be highlighted is the ability of the 
adherent patients to take care of themselves, even though the consequences of nonadherence 
are not visible (such as the replication of the virus or its mutation in resistant strains) or do 
not occur immediately.
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The second dimension of the individual adherence process is affective. It is associated with 
the meaning they construct about illness, because this is an indicator of the relationship they 
establish with HIV infection and, in turn, the degree of acceptance of the diagnosis. From the 
perspective of patients, acceptance of HIV is one of the central conditions for maintaining 
adherence. There are different types of relationships established by highly adherent patients 
with their illness. Some consider that HIV infection is a motivation or challenge that drives 
them to get ahead, that is, a medical condition that acquires a positive meaning because it 
forces them to fight in life.
From a more pragmatic stance, there are patients who perceive illness as a “normal” and man-
ageable health condition. In this case, patients normalize HIV infection in their daily lives, but 
they do not grant it a more transcendental meaning or consider it as a point of transformation 
of the self. However, they consider that they have some control over the medical condition. 
Finally, there are patients who conceive HIV infection as an opportunity to change toward 
a more moderate life. This position seems to make it easier for patients to adopt a healthier 
lifestyle, but at the same time, it may be linked to a desire to rebuild their social identity [29]. 
It seems that attributing a positive sense to illness contributes to adherence, regardless of the 
degree of transcendence granted in the patient’s life or the impact on their identity.
In a third dimension, there are the motivational aspects that favor the adherence process. Highly 
adherent patients indicated three main aspects: (1) loving and taking care of themselves, (2) the 
family, and (3) the desire to live and “move forward” [29]. These motivational elements are not 
important only for the beginning of treatment but especially for its long-term maintenance. 
Adherence can be promoted when patients take care of themselves for the sake of their own 
well-being or because they want to be well for others. Possibly good adherence is an indicator 
of psychological well-being and positive relationships in the patient’s social environment.
The fourth dimension of adherence is of a practical nature and includes the various actions 
or strategies that patients carry out to maintain adherence over time. For pharmacologi-
cal adherence, short-term strategies were identified, such as, the use of external reminders 
(alarms, notes, diaries, or pillboxes), organizing the medication intake at specific moments of 
the daily routine, leaving the medication in special places to remember the intake, taking the 
medication in case of leaving home, reminder of medication intake by relatives, and not stop 
taking the medication if the schedule was not followed. The short-term strategies are focused 
on avoiding forgetfulness, which is the main barrier to pharmacological adherence even in 
highly adherent patients. In the long term, taking the medication is easier because it becomes 
a habit and is remembered mentally. There are also other strategies such as adapting to side 
effects and having willpower, which, unlike the previous strategies, seem to be more idiosyn-
cratic and linked to stoicism [29, 30].
Regarding nonpharmacological adherence, patients indicated strategies according to each 
area of health care [29, 30]:
• Diet. Their strategies are to avoid harmful foods and try to eat healthy foods (low in fat and 
carbohydrates, high in vitamins and minerals).
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• Physical activity. Patients establish an exercise routine or incorporate the activities of their 
daily routine as exercise.
• Rest. The strategies consist of sleeping 7 to 8 hours, not staying up late, and taking naps.
• Substance use. Some patients report having quit smoking or drinking (by willpower and 
not by specialized treatment, especially when there are low levels of previous consump-
tion). In the case of patients who have not stopped drinking, they point out that consump-
tion becomes occasional, only at parties or celebrations.
• Sexual health. Patients use strategies such as refusing to have sex without a condom, 
having condoms available, or creating justifications for condom use (such as avoiding 
pregnancy), especially when there is a difference in power in the couple or they are 
afraid of being discriminated against because of their medical condition. One facilitator 
of these practices is the fear of reinfection or contracting another sexually transmitted 
disease.
• Mental health. Patients resort to strategies such as attending psychological care (individual 
therapy or self-groups), obtaining social support in the family or in religious groups, and 
thinking positively.
• Attendance at medical appointments. Strategies were mentioned such as the use of exter-
nal reminders, saving money to attend the appointment (due to transportation expenses), 
“keeping an eye on the appointment,” or remembering it internally.
• Attendance to laboratory tests. The use of external reminders was pointed out as the only 
strategy. One aspect that facilitates attendance at appointments is the desire to know the 
health status, specifically the viral load and the level of CD4 cells.
The adherence process from the perspective of the individual patient involves the interaction 
between four dimensions. The first dimension comprised beliefs about illness, treatment and 
adherence. These beliefs require coherence with each other and with the explanatory model of 
health personnel. To promote adherence at this level, health education is required to provide 
knowledge on critical aspects of HIV infection. At the same time, it is important that a rela-
tionship be established between the patient and the health personnel where the agreement 
between explanatory models is verified and the dialog is facilitated for the modification of 
beliefs that affect the adherence process.
The second dimension is affective and focuses on the relationship that patients establish with 
their illness. This is an indicator of the degree of acceptance of HIV infection. Patients will not 
elaborate the same meaning about illness, as this depends on the psychosocial impact that 
HIV infection has on their lives. The impact can be diminished by coping strategies and the 
sources of social support they have to manage the consequences of the medical condition in 
daily life. It is important not to force the patient to perceive the HIV infection in a certain way; 
it is necessary to respect his time for acceptance. It is not necessary for the patient to perceive 
the diagnosis as a transcendental event that has transformed their existence or their identity, 
but it is a good indicator for adherence when the patient constructs a positive meaning of 
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illness and considers it a manageable condition. Although the meaning of illness is elaborated 
over time, its acceptance can be promoted through individual therapy. Especially useful are 
the support groups, because the construction of new discourses about living with HIV is pro-
moted within the framework of these social relations.
The third dimension is motivational and consists of identifying those elements that encour-
age the patient to start treatment but, above all, maintain adherence in the long term. The 
main sources of motivation are individual (like the desire to continue living and taking care 
of oneself) and interpersonal (taking care of oneself to be well for others). Both sources are 
important and complement each other, but individual motivations should be emphasized, 
especially when patients have scarce social networks or persistent conflicts exist in their social 
network. Individual or group psychotherapy can strengthen individual motivation, but it is 
also necessary to take into account the role of social support from family members, friends, 
or the couple in patient care to promote interpersonal motivation. It is worth mentioning that 
other possible motivations that can be explored with patients are future goals or plans, since 
self-care is strengthened when there is a specific purpose that is to be achieved in the short, 
medium, or long terms.
The fourth dimension is practical and includes strategies for the two types of adherence. The 
strategies for pharmacological adherence are mainly focused on remembering the medica-
tion, so they can be promoted from health education, by behavioral modeling of strategies 
by health personnel, or through social learning in support groups. Another aspect that needs 
to be addressed is the management of side effects of treatment, which implies a close dialog 
with the health personnel for the monitoring of side effects, to assess whether the patient 
can benefit from medications to reduce side effects or if a change in the treatment scheme is 
required.
Strategies for nonpharmacological adherence can also be promoted from health education, 
individual counseling, or support groups. In each area of health care, it is necessary to moni-
tor the patient’s behavior to establish minimum goals and to evaluate the follow-up of health 
recommendations. In areas where difficulties are detected, problem-solving therapy can be 
used to address the barriers that limit health care and prevent relapse. In case the difficul-
ties are maintained, it is necessary to channel the patient with specialized personnel in each 
area, such as nutritionists, psychotherapists specialized in addictions, or self-support groups 
(Figure 3).
Different barriers may appear through the adherence process, either individual or contex-
tual. For pharmacological adherence, the following individual barriers have been identified: 
forgetfulness of medicine intake, physical discomfort, side effects, and emotional distress. It 
should be noted that patients’ emotional distress is not only linked to their biography and 
personality; it is a suffering with a social origin, because it is linked to stigma and discrimina-
tion processes. As contextual barriers were mentioned, the pending tasks in the domestic or 
work environment that interfere with medication intake. The barriers to nonpharmacological 
adherence for each area of health care are the following [29, 30]:
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• Diet. The individual barrier is the difficulty in leaving junk food. The contextual barrier is 
the economic difficulty to buy healthy foods.
• Physical activity. The main individual barrier is feeling weak or tired. The contextual bar-
rier is the lack of time to exercise.
• Rest. The most frequently mentioned individual barrier was physical discomfort. The main 
contextual barrier was the work schedule.
• Substance use. The individual barriers identified were tobacco addiction and not attending 
specialized help to quit smoking. The contextual barriers identified were friendships that 
consume substances.
• Sexual health. The barriers were identified in the context of the couple relationship. Some 
mentioned that at certain times they did not use the condom because they did not care 
about risk. Also mentioned was the avoidance of sexual relations with a stable partner due 
to the fear of transmitting HIV.
• Mental health. Depression and stigma were the main barriers to mental health. A situation 
mentioned by some patients was the rejection of psychological services or the desire to get 
ahead by themselves.
• Attendance at medical appointments. The individual barriers were forgetfulness and 
physical discomfort. The main contextual barriers were work and not having money for 
transportation.
Figure 3. Dimensions of the adherence process at the individual level.
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• Attendance to laboratory tests. The barrier identified was forgetfulness. It should 
be mentioned that laboratory studies are performed less frequently than medical 
appointments.
Diet is affected not only by the habits developed in the past by the patient but also by the influ-
ence of culture on food preferences, the supply of healthy food in its sociocultural context, 
and feeding practices in the family. It is therefore essential that overweight and obese patients 
can attend a nutritional consultation to continuously monitor their weight and develop a meal 
plan that fits their daily routine and economic capacity.
Physical activity and rest are two areas of health care closely linked to the work context and 
the demands of home. The overload of daily tasks can reduce the time available for rest and 
exercise. If the patient cannot access a job with better conditions for their health, it is impor-
tant to focus on the organization of time to get more rest hours and design a physical activity 
plan that adapts to the patient’s daily routine and can be performed in a short time.
Substance use is an area that requires greater attention in health services. Tobacco addiction 
is usually minimized, and specialized care services are not frequently visited for treatment. 
The consumption of alcohol can be difficult to avoid in a sociocultural context where it is 
promoted as a ritual of socialization, which is why in health services a compromise solu-
tion is usually established: allow the patient to consume alcohol occasionally during spe-
cial situations. However, health services need to send a clear message to patients regarding 
substance use during treatment. It is necessary for health personnel to identify the level of 
substance use in the patient, clearly communicate the consequences of consumption for their 
health and the treatment process, and conduct referral to specialized services in addiction 
care when required.
In the area of sexual health, adherent patients usually adopt condom use in a systematic 
way. However, the problems can be due to a tiredness of the use of the condom, because they 
perceive it as a routine act, which affects spontaneity and eroticism. These situations are not 
usually reported to health personnel, so it is necessary to establish a trust relationship with 
the patient so that they can talk about these issues and request help when necessary. In the 
care services, interventions that address the eroticization of condom use can be implemented.
Especially, it is necessary to be alert when patients are immersed in power relations where the 
negotiation of condom use is limited. On the other hand, some patients report that they have 
stopped having sex for fear of transmitting HIV. In these cases, it may be necessary to provide 
relevant information about transmission risks and protected sex practices. Counseling ses-
sions for the couple can also be developed to clarify doubts about the transmission of HIV and 
provide alternatives for safe sex and protected sex.
The mental health of patients can be compromised from the moment of diagnosis, because 
it generates emotional distress and limits the acceptance of HIV. This is due not only to a 
patient’s vulnerability in psychological terms but also because of the social vulnerability 
associated with their socioeconomic position and the processes of stigma and discrimination. 
Psychological care (at the individual or group level) is essential before starting treatment so 
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that the patient can accept the illness and emotionally prepare to maintain adherence. A prob-
lem is that in health services, care is not usually promoted in an integral way, but mainly 
physical health care is considered and mental health is not sufficiently attended. Another diffi-
culty lies in the rejection of patients to psychological care, either because of the stigma toward 
mental illness or the desire to solve their psychosocial problems individually.
Finally, attendance at medical appointments or laboratory tests is often affected by forgetful-
ness. Reminders via telephone, text message, or social networks can be useful to promote 
adherence in this area. Some patients pointed to work as a barrier, which can be reduced 
if health centers establish a policy for extending the schedules of service. Physical discom-
fort can be a barrier when a health problem makes it difficult to attend the health center, so 
they can benefit from special procedures for changing appointments in such circumstances. 
Certain patients’ report has economic difficulties for transport payment. In certain vulnerable 
groups, financial support may be granted for attendance at medical appointments (Figure 4).
5. Conclusions
Adherence is a process that develops over time, where people living with HIV need to iden-
tify as patients, take an active role in their health care, and establish a collaborative relation-
ship with health personnel. The agency capacity is not the same for all patients; it depends on 
their level of social vulnerability. This means that there are structural conditions that reduce 
the capacity of agency and the options of patients in their daily lives. Patients are not only 
rational subjects who make decisions regarding treatment based on a cost–benefit analysis; 
Figure 4. Individual and contextual barriers during the adherence process.
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they are at the same time affective subjects who need to deal with the rupture of their social 
world caused by a medical condition that is stigmatized in his cultural context.
Adherence has two dimensions: pharmacological and nonpharmacological. At any time 
in the adherence process, patients may become nonadherent, in one or both dimensions. 
The patterns of nonadherence can be generated in the short, medium, and long terms; per-
sistent patterns that extend over time are more problematic. From the perspective of the 
individual patient, adherence is maintained at any point of time due to the interaction of 
the following elements: beliefs about illness, treatment and adherence, affection toward 
HIV infection, motivations, and strategies for taking medication and health care. However, 
the patient may encounter individual and contextual barriers in multiple areas: medication 
intake, diet, rest, physical activity, substance use, sexual health, mental health, attendance 
at medical appointments, and attendance to laboratory tests. Health services require a com-
prehensive evaluation of the patient in each of the areas indicated, in order to understand 
the resources available to the patient for adherence and the barriers that require specific 
interventions.
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